WO2006109091A3 - Sensitisation of cancer cells to dna replication inhibitors - Google Patents

Sensitisation of cancer cells to dna replication inhibitors Download PDF

Info

Publication number
WO2006109091A3
WO2006109091A3 PCT/GB2006/001403 GB2006001403W WO2006109091A3 WO 2006109091 A3 WO2006109091 A3 WO 2006109091A3 GB 2006001403 W GB2006001403 W GB 2006001403W WO 2006109091 A3 WO2006109091 A3 WO 2006109091A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna replication
cancer cells
sensitisation
recql4
replication inhibitors
Prior art date
Application number
PCT/GB2006/001403
Other languages
French (fr)
Other versions
WO2006109091A2 (en
Inventor
Ashok Venkitaraman
Mahesh Sangrithi
Original Assignee
Cambridge Entpr Ltd
Ashok Venkitaraman
Mahesh Sangrithi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd, Ashok Venkitaraman, Mahesh Sangrithi filed Critical Cambridge Entpr Ltd
Publication of WO2006109091A2 publication Critical patent/WO2006109091A2/en
Publication of WO2006109091A3 publication Critical patent/WO2006109091A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to the characterisation of the activity of the RECQL4 protein and the recognition that deficiencies in RECQL4 activity sensitise cancer cells to drugs which inhibit DNA replication. Methods of identifying RECQL4 deficient cancers which are sensitive to drugs which inhibit DNA replication and methods of treating RECQL4 deficient cancers using such drugs are provided.
PCT/GB2006/001403 2005-04-15 2006-04-18 Sensitisation of cancer cells to dna replication inhibitors WO2006109091A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0507685.6 2005-04-15
GBGB0507685.6A GB0507685D0 (en) 2005-04-15 2005-04-15 Cancer treatment

Publications (2)

Publication Number Publication Date
WO2006109091A2 WO2006109091A2 (en) 2006-10-19
WO2006109091A3 true WO2006109091A3 (en) 2007-05-31

Family

ID=34630772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001403 WO2006109091A2 (en) 2005-04-15 2006-04-18 Sensitisation of cancer cells to dna replication inhibitors

Country Status (2)

Country Link
GB (1) GB0507685D0 (en)
WO (1) WO2006109091A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058408A2 (en) 2009-11-10 2011-05-19 National Institute Of Immunology Recql4/recql4 variant-p53 complex for altered mitochondrial function in rothmund-thomson syndrome
CN106191071B (en) * 2016-08-22 2018-09-04 广州资生生物科技有限公司 CRISPR-Cas9 system and application thereof in treating breast cancer diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDO T ET AL: "Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines", JOURNAL OF ORTHOPAEDIC RESEARCH, THE JOURNAL OF BONE AND JOINT SURGERY, INC.,, US, vol. 23, no. 4, July 2005 (2005-07-01), pages 964 - 969, XP004977063, ISSN: 0736-0266 *
LEONARD ANDREA ET AL: "OSTEOGENIC SARCOMA IN THE ROTHMUND-THOMSON SYNDROME", MEDICAL AND PEDIATRIC ONCOLOGY, LISS, NEW YORK, NY, US, vol. 26, no. 4, 1996, pages 249 - 253, XP008071581, ISSN: 0740-8226 *
MERIMSKY O ET AL: "PALLIATIVE EFFECT OF GEMCITABINE IN OSTEOSARCOMA RESISTANT TO STANDARD CHEMOTHERAPY [2]", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 34, no. 8, 1998, pages 1296 - 1297, XP008071588, ISSN: 0959-8049 *
VARUGHESE M ET AL: "OSTEOGENIC SARCOMA AND ROTHMUND THOMSON SYNDROME", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 118, no. 5, 1992, pages 389 - 390, XP008071587, ISSN: 0171-5216 *
WANG L L ET AL: "ASSOCIATIONS BETWEEN OSTEOSARCOMA AND DELETERIOUS MUTATIONS IN THE RECQL4 GENE IN ROTHMUND-THOMSON SYNDROME", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 95, no. 9, 7 May 2003 (2003-05-07), pages 669 - 674, XP008071568, ISSN: 0027-8874 *

Also Published As

Publication number Publication date
WO2006109091A2 (en) 2006-10-19
GB0507685D0 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
WO2005097137A3 (en) Advanced quinazoline based protein kinase inhibitors
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
WO2008033746A3 (en) Tyrosine kinase inhibitors containing a zinc binding moiety
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
EP2433962A3 (en) Identification of tumor-associated antigens for diagnosis and therapy
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2008115719A9 (en) Fused amino pyridine as hsp90 inhibitors
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
UA84954C2 (en) Fused pyrimidones usefuel in the treatment and the prevention of cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
WO2007103146A3 (en) Truncated proteins as cancer markers
WO2008033745A3 (en) Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
EA200901249A1 (en) PROTEINKINAZ BINDING INHIBITORS
EP1805519A4 (en) Wnt proteins and detection and treatment of cancer
EP2261667A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and their therapy of ovarian cancer
WO2007076320A3 (en) Compounds
WO2006109091A3 (en) Sensitisation of cancer cells to dna replication inhibitors
WO2009126804A3 (en) Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
WO2005053614A3 (en) Advanced indolinone based protein kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06726798

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6726798

Country of ref document: EP